Guidelines for Prophylactic G-CSF in Chemotherapy

Risk Assessment for Prophylactic G-CSF Use

Primary prophylactic G-CSF should be administered when the risk of febrile neutropenia exceeds 20% with chemotherapy regimens, or when the risk is 10-20% with additional patient risk factors present, as recommended by the National Comprehensive Cancer Network 1, 2, 3
The American Society of Clinical Oncology recommends primary prophylaxis with G-CSF for chemotherapy regimens with a high risk (>20%) of febrile neutropenia, such as TAC (docetaxel, doxorubicin, cyclophosphamide) for breast cancer, MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) for bladder cancer, and DCF (docetaxel, cisplatin, fluorouracil) for gastric cancer 4
For intermediate-risk regimens (10-20% risk of febrile neutropenia), the National Comprehensive Cancer Network recommends considering G-CSF prophylaxis if patient risk factors are present, such as age ≥65 years, advanced disease, previous chemotherapy or radiation therapy, and poor performance status 1, 3

The European Society for Medical Oncology recommends primary prophylaxis with G-CSF for chemotherapy regimens with a high risk (>20%) of febrile neutropenia, and considers G-CSF prophylaxis for regimens with a 10-20% risk plus patient risk factors 4, 1, 2
The American Society of Clinical Oncology recommends administering filgrastim 5 μg/kg/day subcutaneously, starting 24-72 hours after completion of chemotherapy, until sufficient neutrophil recovery, and pegfilgrastim as a single dose of 6 mg subcutaneously, administered 24 hours after completion of chemotherapy 4, 5

The National Comprehensive Cancer Network recommends avoiding G-CSF administration during concurrent chemoradiotherapy to the chest due to increased risk of complications and death, and monitoring for potential adverse effects, such as bone pain, splenic rupture, and allergic reactions 4, 5, 1

The American Society of Clinical Oncology recommends against routine use of G-CSF for treatment of established febrile neutropenia unless there are factors indicating high risk for infection-related complications, and suggests naproxen (500 mg twice daily) to reduce G-CSF-associated bone pain 1

The European Society for Medical Oncology warns against overuse of G-CSF in low-risk patients, using G-CSF during chest radiotherapy, failing to consider patient-specific risk factors, and administering G-CSF too early (before 24 hours after chemotherapy completion) 4, 5, 1, 2